Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBITDA (2020 - 2025)

Barinthus Biotherapeutics' EBITDA history spans 6 years, with the latest figure at -$11.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 64.5% year-over-year to -$11.0 million; the TTM value through Dec 2025 reached -$56.3 million, up 11.58%, while the annual FY2025 figure was -$56.3 million, 11.64% up from the prior year.
  • EBITDA reached -$11.0 million in Q4 2025 per BRNS's latest filing, up from -$17.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $13.2 million in Q2 2022 to a low of -$30.9 million in Q4 2024.
  • Average EBITDA over 5 years is -$11.6 million, with a median of -$14.3 million recorded in 2023.
  • Peak YoY movement for EBITDA: surged 230.71% in 2022, then tumbled 2180.43% in 2023.
  • A 5-year view of EBITDA shows it stood at -$16.7 million in 2021, then tumbled by 50.55% to -$25.1 million in 2022, then soared by 62.5% to -$9.4 million in 2023, then plummeted by 228.6% to -$30.9 million in 2024, then soared by 64.5% to -$11.0 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's EBITDA are -$11.0 million (Q4 2025), -$17.5 million (Q3 2025), and -$12.8 million (Q2 2025).